Further in Depth Description
Origins of the name “AmealPeptide®”
AmealPeptide® is also known as Lactotripeptides. It was named derived from Mongolian words, “ami” meaning life, and “amil” meaning to revive, recover, and fermentate.
AmealPeptide® was discovered over the course of around 40 years of continuous research into the physiological functions of fermented milk, produced during the process of manufacturing the lactic acid drink CALPIS®.
Key features include its blood pressure-lowering effects and ability to improve cardiovascular functions. AmealPeptide® has an inhibitory activity against angiotensin converting enzyme(ACE). It works on blood vessels by inhibiting enzymes that cause elevated blood pressure, thereby minimizing increases in blood pressure, and by stimulating production of nitric oxide (NO), which helps to protect blood vessels.
Lactotripeptides (AmealPeptide®) is certified as a “food for specified health use” (FOSHU) in Japan and has been granted GRAS approval in the US.
AmealPeptide® is an Informed-Choice and Informed-Sport certified raw material and each batch undergoes banned substance testing, which reassures elite athletes and drug tested consumers that the AmealPeptide ingredient does not lead to failed anti-doping tests.
Lactotripeptides prevent blood pressure from rising by inhibiting enzymes that cause elevated blood pressure.
Mechanism to Make Blood Vessels More Flexible
Lactotripeptides have an effect on blood vessels by stimulating production of substances with vascular protective effects.
The vascular endothelial cells on the inside of blood vessels release factors that regulate blood vessel functions, thereby ensuring that your blood vessels stay healthy. One of the factors that the endothelial cells release is Nitric Oxide (NO).
NO causes blood vessels to dilate, and also has the effect of preventing white blood cells from adhering to blood vessel walls and building up to form deposits. Lactotripeptides stimulate production of NO by vascular endothelial cells, which makes blood vessels more flexible.
PUBLIC RELEASE: 16-MAY-2008
Calpis' AmealPeptide lowers
blood pressure in 2 placebo-controlled trials
supplement produces significant results
New Orleans, LA, May 16 - Two new clinical
trials presented by Calpis Co., Ltd. at the American Society of Hypertension
(ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New
Orleans show that the milk-derived dietary supplement AmealPeptide® reduces
blood pressure in hypertensive patients. The studies, called AHEAD (Achieve
Hypertension Efficacy with AmealPeptide® Dietary Supplement ) II, and the PROBE
(A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose
Response Study confirmed the safety and efficacy of AmealPeptide® for patients
with Stage I and Stage II hypertension.
The AHEAD II study found that the milk-based
product produced a mean drop in daytime, ambulatory systolic blood pressure of
3.6 mmHg for the active group after 6 weeks of treatment. The change was both
statistically and clinically significant. According to JNC 7 (The Seventh
Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure), just a 2 mmHg reduction in systolic
blood pressure results in a 6% reduction in mortality due to stroke and a 4%
reduction in mortality due to coronary heart disease (CHD).
Results of the PROBE study showed
AmealPeptide® to have a dose dependent blood pressure lowering trend and a
reduction of daytime ambulatory blood pressure of 7.6 mmHg (± 8.7) in the 75 mg
a day group and also a significant reduction in 24-hr systolic blood pressure
in the same group of 6.2 mmHg (± 8.4) from the baseline after 8 weeks of
treatment. A lower dose of 5 mg a day of AmealPeptide® also showed blood
pressure lowering effect.
"It's very exciting to see blood pressure
reductions achieved by the food derived substance, AmealPeptide®" stated
Joel Neutel, MD, Associate Clinical Professor of Medicine at the University of
California, Irvine and a specialist in clinical hypertension of the American
Society of Hypertension. "With hypertension and prehypertension on the
rise, physicians and patients need as many effective tools as possible for the
management of this condition," he concluded.
The AHEAD II study enrolled 81 newly diagnosed
stage I and stage II hypertensives. All subjects had a mean daytime systolic
blood pressure between 140 mmHg and 179 mmHg at the start of the trial.
Fifty-two received 75 mg of AmealPeptide® twice a day for 6 weeks, while 29
received a placebo. The PROBE study enrolled 59 diagnosed stage I and stage II
hypertensives who were not taking any antihypertensive medications or who were
uncontrolled on antihypertensive therapy. All subjects had a mean seated
systolic blood pressure between 150 mmHg and 179 mmHg and a mean daytime
systolic blood pressure between 140 mmHg and 179 mmHg at the start of the
trial. All enrolled received AmealPeptide® (5mg, 15mg, 50mg, 75mg a day or 75mg
twice a day) or placebo.
"Calpis takes pride in conducting
research that holds up under serious scientific scrutiny," said Craig
Tillman, Vice President of Sales & Marketing, Calpis USA, Inc. "This
new data confirms that AmealPeptide® can make a difference in those with
elevated blood pressure."
The AHEAD II and PROBE data builds on more
than 11 previous Japanese placebo-controlled clinical studies showing that
AmealPeptide® lowers blood pressure in hypertensives and prehypertensives
without producing the side effects that can be associated with drug therapy.
AmealPeptide® is derived from the milk protein
casein and consists of two tripeptides -- Valine-Proline-Proline (VPP) and
Isoleucine-Proline-Proline (IPP) -- that has been shown to have angiotensin
converting enzyme (ACE) inhibitory characteristics. These peptide sequences
exist naturally in casein. However, they are not released in the gut by the
action of digestive enzymes. They are released by propriety fermentation and
enzymatic processes developed by Calpis Co., Ltd.
Since 1917, Calpis Co., Ltd. has manufactured
and sold fermented and cultured milk-based products. Calpis' innovative
microbiological technology is in the forefront of scientific achievement in
lactic-acid fermentation processing, and has secured its leading position in
the global marketplace. Calpis is the first and only company to isolate
AmealPeptide®, which has been shown to safely lower blood pressure in 13
published, scientific clinical studies. It recently introduced ameal bp®, a
dietary supplement containing AmealPeptide®, in the U.S. market. Calpis is well
known in Asia as a soft drink brand, and in recent years its
AmealPeptide®-based health drinks and dietary supplements have made their mark
on the burgeoning functional foods market in Japan, Europe and the U.S. For more
The American Society of Hypertension, Inc.
(ASH) is the largest US organization devoted exclusively to hypertension and
related cardiovascular diseases. ASH is committed to alerting physicians,
allied health professionals and the public about new medical options, facts,
research findings and treatment choices designed to reduce the risk of
cardiovascular disease. For more information, visit
Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects.
Lactobacillus helveticus LBK-16H-fermented milk
products containing tripeptides isoleucine-proline-proline and
valine-proline-proline lower blood pressure in hypertensive subjects using
office and home blood pressure registration. The present study was aimed to
evaluate the effects of two doses of these lactotripeptides on 24-h ambulatory
blood pressure and lipidomics profiles in mildly hypertensive subjects.
In a randomized, double-blind,
placebo-controlled parallel group study, 89 mildly hypertensive subjects
ingested, after a 1-month run-in period, a fermented milk drink with 5 mg per
day of lactotripeptides during 3 months, and a milk drink with 50 mg per day of
lactotripeptides for the following 3 months, or a placebo milk drink without
lactotripeptides. Ambulatory blood pressure (24 h) was recorded at baseline and
at the end of the intervention periods. Lipidomics profiles were characterized
before and after the 6-month intervention.
After the second intervention period (50 mg per
day of lactotripeptides), systolic and diastolic 24-h blood pressures decreased
significantly in the peptide, but not in the placebo group. However, the
treatment effects -2.6 mm Hg (95% confidence interval (CI): -5.7 to 0.4) in
systolic and -1.3 mm Hg (95% CI: -3.4 to 0.8) in diastolic blood pressure did
not reach statistic significance. Ingestion of 5 mg per day of lactotripeptides
for 3 months did not lower blood pressure. The peptide group was dominated by
decrease in multiple phospholipids (PL).
Ingestion of fermented milk with daily dose of
50 mg of lactotripeptides appears to lower elevated blood pressure slightly
from the baseline, but not significantly compared with the placebo group and to
induce significant decreases in multiple PL.
blood pressure lowering effect of lactotripeptides and salt intake in 24-h
ambulatory blood pressure measurements.
It is well known that the sour milk containing
lactotripeptides has a blood pressure lowering effect. The aim of this study
was to evaluate the blood pressure (BP) lowering effect of lactotripeptides by
monitoring home blood pressure, 24-h ambulatory measurements (ABPM), and daily
urinary salt excretion. A total of 30 volunteers were given 200 ml of sour milk
twice a day for 8 weeks after a 1-week run-in period. This preparation
contained the lactotripeptides valine-proline-proline 2.66 mg and isoleucine-proline-proline
1.38 mg. The study participants had daily measurements of urinary salt
excretion determined by an electric salt sensor and home blood pressure for
each week during the run-in period, before the 4-and 8-week time points. 24-h
ABPM was measured at the end of each week. Mean systolic blood pressure (SBP)
during night sleep including base BP at 4 and 8 weeks were significantly lower
than baseline values. Mean SBP and diastolic blood pressure (DBP) during night
sleep of the 22 participants who belonged to the criteria of hypertension by
24-h ABPM was significantly decreased at 4 and 8 weeks. The change in 24-h mean
SBP significantly correlated with mean urinary salt excretion over the three
measurement periods. The 22 hypertensive subjects without taking
lactotripeptides did not show significant change of blood pressure during 24
hours at 4 and 8 weeks. Our study confirmed the BP lowering effect of
lactotripeptides during night-time sleep and showed that a lower intake of salt
may increase the BP lowering effect of lactotripeptides through 24 hours in
Amealpeptide data :
ACE Inhibitor effectiveness